COMUNICADO: Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-m

Publicado 30/06/2017 14:03:49CET

Part of Debiopharm Group(TM) - a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management - Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit [ ] .

We are on Twitter. Follow us @DebiopharmNews at

[1] Klein K, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016;29(11):1241-1248.

[2] Muir A. Precocious puberty. Pediatr Rev. 2006;27:373-381.

[3] Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358 (22):2366-2377.

[4] Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs. 2004;6:211-231.

[5] Partsch CJ, Sippell WG. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab.2002;16:165-189.


Debiopharm International SA Contact Christelle Tur Communication Coordinator Tel: +41(0)21-321-01-11 Arbor Pharmaceuticals, LLC Contact Amanda Sellers Spectrum Science Communications Tel: +1-404-865-3597

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación